Enduro Royalty Trust NDRO 深 滬
等待開盤 09-09 09:30:00 美东时间
3.65
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.65
- 總市值 1.20亿
- 52周最高 4.45
- 市盈率 靜 2.43
- 換手率 0.00%
- 52周最低 2.75
- 委 比 0.00%
- 總股本 3300.00万
- 歷史最高 22.02
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.77
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas...
06-17 20:08
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New Engla...
06-02 20:04
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif., April 11, 20...
04-11 21:00
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, inclu...
2024-06-14 15:05
服饰美妆新装上阵，海内外大牌新品组团亮相京东3·8节
转自：大众报业·齐鲁壹点 随着3·8节的来临，广大消费者置新装、焕新妆的热情高涨。京东服饰美妆3·8节已全面开启，带来覆盖美妆护肤、男女装、运动鞋服、黄金珠宝...
2024-03-04 10:42
新春开工换新装！京东携手SANDRO、太平鸟、杰克·琼斯等品牌助力解锁春日活力
春日的阳光正在逐渐驱散冬天的寒意，不少小伙伴也准备从轻松的春节假日回归到紧张有序的职场节奏里。新年新气象，新春换新装，2月18日至2月24日，京东服饰美妆“返工...
2024-02-19 10:17
NEW YORK COMMUNITY BANCORP, INC APPOINTS ALESSANDRO DINELLO AS EXECUTIVE CHAIRMAN
HICKSVILLE, N.Y., Feb. 7, 2024 /PRNewswire/ -- New York Community Bancorp, Inc. (NYSE: NYCB) (the "Company") today announced the appointment of Alessandro (Sandro) DiNello as Executive Chair...
2024-02-07 20:45
Rigel Pharmaceuticals Provides Business Update
Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 mill...
2024-01-08 21:05
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data Reinforce KYPROLIS® (carfilzomib) as...
2023-12-08 22:00
安进在 2023 年 ASH 上重点介绍血液学产品组合
THOUSAND OAKS, Calif., Dec. 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today a...
2023-12-08 01:00
